These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

602 related articles for article (PubMed ID: 33186537)

  • 1. New therapies for neuromyelitis optica spectrum disorder.
    Levy M; Fujihara K; Palace J
    Lancet Neurol; 2021 Jan; 20(1):60-67. PubMed ID: 33186537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
    Cree BAC; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; She D; Rees W; Smith M; Cimbora D; Katz E; Bennett JL;
    Lancet Neurol; 2024 Jun; 23(6):588-602. PubMed ID: 38760098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Wallach AI; Tremblay M; Kister I
    Neurol Clin; 2021 Feb; 39(1):35-49. PubMed ID: 33223088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of treatments in Neuromyelitis optica to modify the course of disease in adult patients. Systematic review of literature.
    Velasco M; Zarco LA; Agudelo-Arrieta M; Torres-Camacho I; Garcia-Cifuentes E; Muñoz O
    Mult Scler Relat Disord; 2021 May; 50():102869. PubMed ID: 33711580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Network Meta-analysis of Food and Drug Administration-approved Treatment Options for Adults with Aquaporin-4 Immunoglobulin G-positive Neuromyelitis Optica Spectrum Disorder.
    Wingerchuk DM; Zhang I; Kielhorn A; Royston M; Levy M; Fujihara K; Nakashima I; Tanvir I; Paul F; Pittock SJ
    Neurol Ther; 2022 Mar; 11(1):123-135. PubMed ID: 34773597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Neuromyelitis Optica Pathogenesis: Results from Randomized Controlled Trials of Biologics.
    Cacciaguerra L; Tortorella P; Rocca MA; Filippi M
    Neurotherapeutics; 2021 Jul; 18(3):1623-1636. PubMed ID: 33909234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders.
    Valencia-Sanchez C; Wingerchuk DM
    BioDrugs; 2021 Jan; 35(1):7-17. PubMed ID: 33301078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the treatment of neuromyelitis optica spectrum disorders.
    Romeo AR
    Curr Opin Rheumatol; 2021 May; 33(3):233-239. PubMed ID: 33741809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Satralizumab in the treatment of neuromyelitis optica spectrum disorder.
    Duchow A; Bellmann-Strobl J
    Neurodegener Dis Manag; 2021 Feb; 11(1):49-59. PubMed ID: 33167776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder.
    Clardy SL; Pittock SJ; Aktas O; Nakahara J; Isobe N; Centonze D; Fam S; Kielhorn A; Yu JC; Jansen J; Zhang I
    Neurol Ther; 2024 Jun; 13(3):535-549. PubMed ID: 38722571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders.
    Paton DM
    Drugs Today (Barc); 2021 Mar; 57(3):209-218. PubMed ID: 33729218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder.
    Maillart E; Renaldo F; Papeix C; Deiva K; Bonheur J; Kwon T; Boespflug-Tanguy O; Germanaud D; Marignier R
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32098863
    [No Abstract]   [Full Text] [Related]  

  • 13. Blockade of IL-6 signaling in neuromyelitis optica.
    Araki M
    Neurochem Int; 2019 Nov; 130():104315. PubMed ID: 30342072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study.
    Pittock SJ; Lennon VA; McKeon A; Mandrekar J; Weinshenker BG; Lucchinetti CF; O'Toole O; Wingerchuk DM
    Lancet Neurol; 2013 Jun; 12(6):554-62. PubMed ID: 23623397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuromyelitis optica spectrum disorder with increased aquaporin-4 microparticles prior to autoantibodies in cerebrospinal fluid: a case report.
    Bejerot S; Hesselmark E; Mobarrez F; Wallén H; Hietala MA; Nybom R; Wetterberg L
    J Med Case Rep; 2019 Jan; 13(1):27. PubMed ID: 30696485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An update on biologic treatments for neuromyelitis optica spectrum disorder.
    Kim W; Kim HJ
    Expert Rev Clin Immunol; 2023 Jan; 19(1):111-121. PubMed ID: 36414430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders.
    Gao Y; Zhang B; Yang J
    Ann Pharmacother; 2021 Sep; 55(9):1167-1171. PubMed ID: 33246373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drugs for the treatment of neuromyelitis optica.
    Duchow A; Chien C; Paul F; Bellmann-Strobl J
    Expert Opin Emerg Drugs; 2020 Sep; 25(3):285-297. PubMed ID: 32731771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Monoclonal Antibody Therapy in Neuromyelitis Optica Spectrum Disorders: Evidence from Randomized Controlled Trials.
    Xue T; Yang Y; Lu Q; Gao B; Chen Z; Wang Z
    Mult Scler Relat Disord; 2020 Aug; 43():102166. PubMed ID: 32442886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial.
    Rensel M; Zabeti A; Mealy MA; Cimbora D; She D; Drappa J; Katz E
    Mult Scler; 2022 May; 28(6):925-932. PubMed ID: 34595983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.